The FDA has accepted Seattle Genetics’ sBLA for filing of Adcetris for retreatment and extended duration beyond 16 cycles of therapy in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
For patients with chronic neutrophilic leukemia and atypical chronic myeloid leukemia, activating mutations in the gene encoding the colony stimulating factor 3 receptor are common.
At least one nonsynonymous mutation in a gene relevant for pathogenesis seen in nearly all cases
Using autologous T-cell immunotherapy to attack leukemia cells showed early promise in two children diagnosed with relapsing acute lymphoblastic leukemia after bone marrow transplant, according to research presented at AACR 2013.
Ibrutinib is well tolerated and highly effective in patients with chronic lymphocytic leukemia, according to research presented at AACR 2013.
Increased exposure to traffic-related air pollution during pregnancy and early life was associated with a higher incidence of acute lymphoblastic leukemia, retinoblastoma, and germ cell tumors, according to research presented at AACR 2013.
Five patients with relapsed B cell acute lymphoblastic leukemia quickly achieved complete remission after treatment with autologous engineered T cells.
Using molecular biomarkers for precise risk stratification can save young patients from enduring treatments they may not otherwise need.
Among patients treated for Hodgkin lymphoma , long-term excess mortality due to diseases of the circulatory system is expected to continue to decline.
Diagnovus announced the launch of Engauge-cancer-DLBCL, the first commercial gene expression assay to aid physicians in risk stratification and treatment of patients with diffuse large B-cell lymphoma (DLBCL).
